According to a study by the AAA Foundation for Traffic Safety, people become better drivers with age and experience, at least until old age sets in. For the same number of miles driven, rates of both crashes and deaths are relatively high among 16-17-yr-olds, decline steadily with age until 70, and then rise again.
None of this should be a surprise; new drivers lack the experience that comes with a long history of driving, and older drivers are beginning to lose their sensory acuity and reaction times. But the numbers are startling. For the same number of miles driven, 16-17-yr-old drivers are about 6 times as likely to crash (and to die in a crash) as the safest group of drivers, 60-69-yr-olds. So, too, are drivers over the age of 80.
Traffic safety experts have been aware of these facts for some time. That is why some states now limit the conditions under which younger drivers can drive (forbidding driving with other teenagers or driving at night, for example). Most states require older drivers to have a vision test to renew their licenses, and a few states require older drivers to take a written test or a road test as well. All this seems to be working, as the number of people killed in automobile crashes declined more than 25% between 1995 and 2010.
Incidentally, teen crashes and deaths go up about 15% in the summer, when teens are out of school and may be driving more than during the school year.
Wednesday, July 5, 2017
Saturday, July 1, 2017
A Skin Patch to Deliver the Flu Vaccine - An Update
Remember the skin patch (this blog, Mar 13, 2014) that was being developed to deliver vaccines without an injection? Back then, the patch had only been tested to see how well the dissolvable microneedles of the patch would be tolerated by patients. Last week the same researchers reported that it has now been tested with the flu vaccine.
In the latest study, healthy volunteers received the flu vaccine either by skin patch or by the usual syringe and needle, both administered by a health care worker. An additional group of volunteers were instructed to administer the skin patches themselves, to determine if self-administration was as effective as administration by a health care worker. The results were encouraging. Increases in antibody titers (a sign of immune system activation) were the same in both of the groups that used skin patches and the group that received an injection. Furthermore, the number of adverse reactions was similar in all groups. In other words, the skin patches seemed to deliver the vaccine safely and effectively, even when the patches were self-administered.
So are we done? Not quite. This was a Phase 1 study; a small number of volunteers was recruited to test the method's safety and potential effectiveness (in this case, potential effectiveness was assessed as an increase in antibody titer). A much larger study will be needed to see if the skin patch vaccine delivery method actually reduces the incidence of the flu. A much larger group of patients will be needed, since not everyone in a population gets the flu. This part of the study will probably take at least several more years.
Perhaps some day you'll be able to order a flu vaccine skin patch on the internet, have it delivered through the mail (or by a drone!), and administer it yourself. Today we're one step closer to that goal.
In the latest study, healthy volunteers received the flu vaccine either by skin patch or by the usual syringe and needle, both administered by a health care worker. An additional group of volunteers were instructed to administer the skin patches themselves, to determine if self-administration was as effective as administration by a health care worker. The results were encouraging. Increases in antibody titers (a sign of immune system activation) were the same in both of the groups that used skin patches and the group that received an injection. Furthermore, the number of adverse reactions was similar in all groups. In other words, the skin patches seemed to deliver the vaccine safely and effectively, even when the patches were self-administered.
So are we done? Not quite. This was a Phase 1 study; a small number of volunteers was recruited to test the method's safety and potential effectiveness (in this case, potential effectiveness was assessed as an increase in antibody titer). A much larger study will be needed to see if the skin patch vaccine delivery method actually reduces the incidence of the flu. A much larger group of patients will be needed, since not everyone in a population gets the flu. This part of the study will probably take at least several more years.
Perhaps some day you'll be able to order a flu vaccine skin patch on the internet, have it delivered through the mail (or by a drone!), and administer it yourself. Today we're one step closer to that goal.
Topics:
cells and stem cells,
infectious disease
Tuesday, June 27, 2017
Compounding Pharmacy Executive Goes to Prison
The co-founder and head pharmacist of a now-bankrupt New England compounding pharmacy has finally been sentenced to prison. Under his direction the pharmacy failed to ensure the sterility and safety of its products, which ultimately killed 76 people (see this blog, Jan 2, 2015).
Although the executive's conviction and sentencing finally closes this unfortunate case, not everyone is satisfied with the verdict. The executive was cleared of charges of second-degree murder that might have resulted in a 35-year sentence. Instead, he was convicted of racketeering and fraud, for which he will spend only 9 years in prison.
Although the executive's conviction and sentencing finally closes this unfortunate case, not everyone is satisfied with the verdict. The executive was cleared of charges of second-degree murder that might have resulted in a 35-year sentence. Instead, he was convicted of racketeering and fraud, for which he will spend only 9 years in prison.
Saturday, June 24, 2017
Fear of Vaccines
Why does the notion that vaccines cause autism continue to persist, despite all the scientific evidence to the contrary? In a recent essay, a science writer and father argues that it's all about one of our most basic emotions - fear. According to the author of the article, fear is just too strong an emotion to be overcome by logic or evidence.
If he's right, then continuing to try to convince anti-vaccine advocates with more scientific evidence just isn't going to work. Their fear will have to be acknowledged and addressed. How to do that is a question for which the author doesn't yet have an answer.
If he's right, then continuing to try to convince anti-vaccine advocates with more scientific evidence just isn't going to work. Their fear will have to be acknowledged and addressed. How to do that is a question for which the author doesn't yet have an answer.
Thursday, June 22, 2017
New Treatment for Chronic Knee Pain
What are your options for reducing chronic pain? Certain drugs are good at reducing pain, of course, but some of the most effective ones are dangerously addictive when used for more than a few days. Cortisol injections can reduce the pain from certain types of arthritis. That used to be about it. But now there's a new method is called "cooled radiofrequency therapy", or CooliefTM for short.
Coolief is a non-invasive, outpatient technique designed to block pain for prolonged periods. Radiofrequency energy is applied to needles inserted into the site of pain. The radiofrequency energy heats sensory nerve endings, damaging them and blocking their ability to transmit pain signals. Because the radiofrequency energy heats up the needles, the needles are simultaneously cooled to avoid widespread tissue damage. The result is immediate relief from pain. And because damaged sensory nerve endings take a long time to heal, the pain relief can last for up to 24 months.
The technique is currently FDA-approved for the treatment of osteoarthritic knee pain, but it's been used to treat chronic back pain as well. It is likely that the technique will gain further FDA approvals in the not-too-distant future. The cost (about $4,000) is covered by some health insurance policies.
If the Coolief technique proves to be both safe and effective in treating different sources of chronic pain, some day physicians may be able to stop writing so many prescriptions for addictive pain-killers!
Coolief is a non-invasive, outpatient technique designed to block pain for prolonged periods. Radiofrequency energy is applied to needles inserted into the site of pain. The radiofrequency energy heats sensory nerve endings, damaging them and blocking their ability to transmit pain signals. Because the radiofrequency energy heats up the needles, the needles are simultaneously cooled to avoid widespread tissue damage. The result is immediate relief from pain. And because damaged sensory nerve endings take a long time to heal, the pain relief can last for up to 24 months.
The technique is currently FDA-approved for the treatment of osteoarthritic knee pain, but it's been used to treat chronic back pain as well. It is likely that the technique will gain further FDA approvals in the not-too-distant future. The cost (about $4,000) is covered by some health insurance policies.
If the Coolief technique proves to be both safe and effective in treating different sources of chronic pain, some day physicians may be able to stop writing so many prescriptions for addictive pain-killers!
Saturday, June 10, 2017
Chondroitin as a Treatment for Osteoarthritis
The dietary supplement chondroitin has been selling for a long time as a treatment for joint pain due to osteoarthritis. Recently I've even seen advertisements promoting the use of glucosamine/chondroitin (chondroitin is almost always sold in combination with glucosamine) in pets. I suppose the theory is that if works for humans, then it should work for pets.
And yet, chondroitin hasn't actually been shown convincingly to reduce joint pain (see this blog Oct. 6, 2010). With that as background, a new study now purports to show that high-quality pharmaceutical-grade chondroitin (not the ordinary over-the-counter stuff) actually does reduce joint pain in people suffering from knee arthritis. In fact, chondroitin allegedly worked as well as the popular prescription nonsteroidal anti-inflammatory drug, celecoxib.
So chondroitin works, right? Not so fast. According to the footnotes in the article, the study was sponsored (i.e. funded) by a pharmacy company that makes pharmaceutical-grade chondroitin. It's not hard to imagine that the company has a financial interest in the study's outcome. The company even provided "editorial assistance" to the author prior to the article's publication.
Putting all that possible bias aside for a moment, the data show a minimal effect of chondroitin at best. According to Figure 1 in the article, at six months of treatment both chondroitin and celecoxib reduced patients' reported knee pain significantly. However, patients in the placebo group (receiving neither drug) also reported a reduction in pain, by nearly the same amount. In other words, most of the patients' reported pain reduction was caused just by being enrolled in the study and thinking that they might be receiving a drug that worked.
Before I accept that chondroitin definitively reduces the knee pain of arthritis, I'd want to see this study repeated in an independent study.
And yet, chondroitin hasn't actually been shown convincingly to reduce joint pain (see this blog Oct. 6, 2010). With that as background, a new study now purports to show that high-quality pharmaceutical-grade chondroitin (not the ordinary over-the-counter stuff) actually does reduce joint pain in people suffering from knee arthritis. In fact, chondroitin allegedly worked as well as the popular prescription nonsteroidal anti-inflammatory drug, celecoxib.
So chondroitin works, right? Not so fast. According to the footnotes in the article, the study was sponsored (i.e. funded) by a pharmacy company that makes pharmaceutical-grade chondroitin. It's not hard to imagine that the company has a financial interest in the study's outcome. The company even provided "editorial assistance" to the author prior to the article's publication.
Putting all that possible bias aside for a moment, the data show a minimal effect of chondroitin at best. According to Figure 1 in the article, at six months of treatment both chondroitin and celecoxib reduced patients' reported knee pain significantly. However, patients in the placebo group (receiving neither drug) also reported a reduction in pain, by nearly the same amount. In other words, most of the patients' reported pain reduction was caused just by being enrolled in the study and thinking that they might be receiving a drug that worked.
Before I accept that chondroitin definitively reduces the knee pain of arthritis, I'd want to see this study repeated in an independent study.
Sunday, June 4, 2017
Advance Directives, and Suing for "Wrongful Life"
When it comes to their last moments, some medical patients would prefer to die gently without having their chest opened, their heart shocked, or their breathing taken over by a pump, especially if their chances of a meaningful recovery are low. To that end, many patients sign advance directives that are intended to provide a clear statement of their wishes. Hospitals often encourage patients to sign an advance directive because it can provide guidance to the medical team when (or if) patients can no longer speak for themselves.
But what happens when the medical team doesn't honor a patient's advance directive? This is not as far-fetched as it might seem. Physicians are trained to save lives, and it's difficult for them to watch a patient die when they know that a procedure might keep the patient alive, if even only for a while. If a patient is kept alive by medical measures specifically not wanted as documented by their advance directive, should damages be awarded for "wrongful life"? It all boils down to whether an advance directive should be viewed as only advisory, or whether it should be considered similar to a legal document.
This is a legal grey zone that is now being tested by several "wrongful-life" lawsuits. Traditionally, courts have been reluctant to punish doctors who aggressively work to save their patients. But recent court decisions suggest that the tide may be turning to favor the patient, according to an article in The New York Times. Time will tell.
Do you have an advance directive? You'll probably be asked that question the next time you visit an emergency room or are admitted to a hospital. The question is; even if you do, will it be honored?
But what happens when the medical team doesn't honor a patient's advance directive? This is not as far-fetched as it might seem. Physicians are trained to save lives, and it's difficult for them to watch a patient die when they know that a procedure might keep the patient alive, if even only for a while. If a patient is kept alive by medical measures specifically not wanted as documented by their advance directive, should damages be awarded for "wrongful life"? It all boils down to whether an advance directive should be viewed as only advisory, or whether it should be considered similar to a legal document.
This is a legal grey zone that is now being tested by several "wrongful-life" lawsuits. Traditionally, courts have been reluctant to punish doctors who aggressively work to save their patients. But recent court decisions suggest that the tide may be turning to favor the patient, according to an article in The New York Times. Time will tell.
Do you have an advance directive? You'll probably be asked that question the next time you visit an emergency room or are admitted to a hospital. The question is; even if you do, will it be honored?
Topics:
development and aging,
science and society
Subscribe to:
Posts (Atom)